Viz.ai, a San Francisco, CA, and Tel Aviv, Israel and -based AI-powered illness detection and care coordination platform, raised $100m in Sequence D funding spherical at a $1.2 billion valuation.
The spherical was led by Tiger World and Perception Companions with participation from early backers, together with Scale Ventures, Kleiner Perkins, Threshold, GV (previously Google Ventures), Sozo Ventures, CRV, and Susa.
The corporate intends to make use of the brand new funds to broaden the platform to detect and triage further ailments, and develop its buyer base globally.
Led by Chris Mansi, MD, co-founder and CEO, Viz.ai leverages AI algorithms and machine studying to extend the pace of analysis and take care of a wide range of acute and emergent ailments throughout hospitals and well being methods. The clever care coordination answer unifies synchronized care collaboration, excessive constancy cellular picture viewing, automated workflows and improved visibility at decision-making moments. Viz.ai’s complete neurovascular and vascular AI platform is clinically confirmed to avoid wasting time and enhance affected person outcomes and entry to care and is utilized in greater than 1,000 hospitals within the US and EMEA.Clients embrace Mount Sinai Well being System, Thomas Jefferson College, Banner Well being, CommonSpirit Well being, and HCA Healthcare, which can also be an investor.
The corporate is situated in San Francisco, Tel Aviv, Portugal and Amsterdam.